New progress and application of molecular diagnosis and targeted therapy of thyroid cancer
10.3760/cma.j.cn.115807-20210626-00199
- VernacularTitle:甲状腺癌分子诊断和靶向治疗的新进展及应用
- Author:
Yingchao ZHANG
1
;
Xianzhao DENG
;
Bomin GUO
;
Zheng DING
;
Zhili YANG
;
Bo WU
;
Youben FAN
Author Information
1. 上海交通大学附属第六人民医院甲乳疝外科，上海交通大学甲状腺疾病诊治中心 200233
- Keywords:
Thyroid cancer;
Molecular diagnosis;
Tyrosine kinase inhibitors;
Targeted therapy;
Neoadjuvant therapy
- From:
Chinese Journal of Endocrine Surgery
2021;15(5):546-550
- CountryChina
- Language:Chinese
-
Abstract:
The occurrence and progression of thyroid cancer are related to a series of molecular changes and the activation of signaling pathways, which is the basis of targeted therapy. For inoperable locally advanced, metastatic and refractory thyroid cancer, especially anaplastic thyroid cancer, the efficacy of targeted therapies, particularly tyrosine kinase inhibitors (TKIs) , has been demonstrated in clinical trials. TKIs can relieve clinical symptoms, improve patients’quality of life, prolong the progress free survival, and even create opportunities for radical operation or reoperation. This article reviews and summarizes the key molecular events in tumorigenesis and progression of thyroid cancer, and analyzes the results of clinical studies on the efficacy and safety of different TKIs in refractory advanced thyroid cancer, in order to provide reference and assistance for individualized targeted therapy of patients.
